Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines.

International journal of oncology - 1 Aug 2012

Kneissl Julia, Keller Simone, Lorber Thomas, Heindl Stefan, Keller Gisela, Drexler Ingo, Hapfelmeier Alexander, Höfler Heinz, Luber Birgit

Abstract excerpt

The therapeutic activity of the epidermal growth factor receptor (EGFR)-directed monoclonal antibody cetuximab in gastric cancer is currently being investigated in clinical studies. Reliable biomarkers for the identification of patients who are likely to benefit from this treatment are not available. In this study, we assessed the activity of cetuximab in five...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epidermal Growth Factor

Share to Glycoproteins

Share to Intercellular Signaling Peptides and Proteins

Share to Protein Processing, Post-Translational

Share to Proto-Oncogene Proteins c-met

Share to ras Proteins

Source

Identifiers

PMID: 22614881
DOI: 10.3892/ijo.2012.1479

Genes

AREG
EGFR
KRAS
MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines.PMID 22614881Read ↗

Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines.Semantic proximity Read ↗

A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.Semantic proximity Read ↗

Model-based analysis of response and resistance factors of cetuximab treatment in gastric cancer cell linesSemantic proximity Read ↗

Evaluation of epidermal growth factor receptor signaling effects in gastric cancer cell lines by detailed motility-focused phenotypic characterization linked with molecular analysis.Semantic proximity Read ↗

Development of Acquired Resistance in Alpelisib-treated Gastric Cancer Cells WithPIK3CAMutations and Overcoming StrategiesSemantic proximity Read ↗

Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines.Semantic proximity Read ↗

EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient‑derived xenografts with cetuximab.Semantic proximity Read ↗

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Semantic proximity Read ↗

Cetuximab inhibits gastric cancer growth in vivo, independent of KRAS status.Semantic proximity Read ↗

In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.Semantic proximity Read ↗

Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibitionSemantic proximity Read ↗

EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.